Trasylol Lawyer
Trasylol News
Remaining Trasylol Stock Pulled from Market
Category: Trasylol News
Bayer is pulling any remaining stock of Trasylol from the market after the final results of the BART study were published in the New England Journal of Medicine yesterday. Sales of the anti-bleeding drug were halted last year after preliminary results showed a fifty percent increase in death after its use. The drug still remained in inventory at some hospitals for use in cases that met strict guidelines.
Continue reading "Remaining Trasylol Stock Pulled from Market"
Trasylol puts 10,000 Floridians at Risk
Category: Trasylol News
As more data is released, people are able to see just how widespread and devastating the effects of Trayslol are. In Florida, it is estimated that nearly 10,000 patients have either lost their lives or seriously compromised their health as a result of Trayslol. http://www.lawyersandsettlements.com/articles/10143/trasylol-10000.html According to Dr. Dennis Magano, approximately 22,000 lives could have been saved if the manufacturers of Trasylol would have taken the product off the market two years earlier than the recall. At that time, the manufacturer had enough evidence to determine that Trasylol was potentially harmful.
"Instead, Bayer is alleged to have suppressed evidence and soft-pedaled the issue in an effort to keep Trasylol on the market. It was only when faced with insurmountable evidence suggesting Trasylol was potentially harmful, that Bayer finally acted and pulled Trasylol altogether." http://www.lawyersandsettlements.com/articles/10143/trasylol-10000.html
"At its peak, Trasylol was being used in two-thirds of all open-heart surgical procedures.
Mangano estimates that over the two years between his original call for the removal of Trasylol, and when the drug was finally recalled last November 431,000 patients were administered the drug. Of those, Mangano calculates that 22,000 died. That leaves 409,000 who either were not affected by the drug, or are having to deal with a litany of health problems and adverse effects, not the least of which is renal failure, or failure of the kidney. Heart attack and stroke has also been linked to Trasylol.
What raises Viles' ire is the fact that patients are not routinely told what drugs are used during their surgery, unless the patient is proactive and request their medical records.
Therefore, patients could have been given Trasylol during the course of an open-heart surgical procedure and never know it." http://www.lawyersandsettlements.com/articles/10143/trasylol-10000.html
1,000 People Died Each Month From Trasylol
Category: Trasylol News
A researcher that was responsible for such important work as discovering a daily aspirin can reduce the risk of heart attack has stated that 1,000 people a month have died when Trasylol was being used regularly. Trasylol is a drug used in open heart bypass surgery to reduce the amount of blood lost. Studies performed on patient data has shown an increased risk of kidney failure from Trasylol use.
Continue reading "1,000 People Died Each Month From Trasylol"
60 Minutes News Story: Deaths & Kindey Failure Related to Trasylol
Category: Trasylol News
This evening, 60 Minutes, the famous investigative TV news show, reported on medical studies which show that use of the drug Trasylol was linked to acute renal failure and death when used in heart surgeries. The lead story on 60 minutes profiled the heart surgery, kidney failure, amputations and eventual death of Joseph Randone after Trasylol was used. According to the surviving family members, the surgeon alerted them to a story on Trasylol and informed them that he believed Trasylol had been to blame in their father's death.
Read more about the Trasylol complications and the Randone Family's story on InjuryBoard.com.
FDA Reacted to Slowly to Trasylol Threat
Category: Trasylol News
A researcher from San Francisco was working on a study in 2005 that showed that Trasylol increased the risk of kidney failure. Dr. Joseph Mangano performed the study on data from over 5,000 patients. He believes that for every month that the FDA failed to pull Trasylol from the market 1,000 people died after using the drug. Trasylol is used during open heart surgery to reduce bleeding. It took another large study in Canada before the FDA acted though. Following the BART study Trasylol was pulled from the market in November 2007.
ACE Inhibitors Increase Trasylol Risk
Category: Trasylol News
A new report from British researchers is showing that the risks of kidney failure when using Trasylol increased when also used with ACE inhibitors during off-pump open heart surgery. Off-pump surgery meaning the heart is beating and no bypass machine is used. Patients that received Trasylol during surgery on a bypass machine had no increase risk of injury. Aprontinin is the generic name for Trasylol.
Duluth Health System Bans Trasylol Pens
Category: Trasylol News
A health-care system in Duluth, Minnesota has banned all drug related freebies from their offices and buildings. That means no more pens or pads of paper labeled with names such as Trasylol, Vytornin, or Avandia. The SMDC Health System Administrators didn't want doctors influenced by the freebies.
CHM Suspends Trasylol License
Category: Trasylol News
The Commission for Human Medicine has reviewed data from the BART study that was performed in Canada on the anti-bleeding drug Trasylol. Trasylol was recalled in early November after the BART study showed the drug increased the risk of death by fifty percent over other drugs in the same class. The CHM announced they have suspended Trasylol's license.
Aprotinin Banned in China
Category: Trasylol News
Aprotinin is the generic name for Trasylol. Aprotinin has been used in China as a post-surgery drug used to control bleeding. It is not manufactured by Bayer in China. Due to recent reports that Trasylol was recalled around the world, the Chinese government has banned the use of aprotinin.
Long Island Hospital Limited the Use of Trasylol
Category: Trasylol News
A hospital in Long Island limited the use of the anti-bleeding drug Trasylol in 2006, long before the drug was pulled from the market. Long Island Jewish surgeons have only used Trasylol in a small number of cases in order to limit risks to their patients. The drug was pulled from the market after a study showed an increased risk of kidney failure, heart attack and strokes.
Continue reading "Long Island Hospital Limited the Use of Trasylol"
United Kingdom Commission Recommends Suspension of Trasylol
Category: Trasylol News
A commission in the United Kingdom has recommended that a marketing suspension for the anti-bleeding drug Trasylol until further studies can be done. The Commission for Human Medicine (CHM) will be watching a European study to see what action to take next. The study is expected to take 3 months.
Continue reading "United Kingdom Commission Recommends Suspension of Trasylol"
Trasylol May be Recalled in Europe
Category: Trasylol News
Trasylol has been pulled from the market in the United States and regulators in Europe are posed to do the same. The European Medicines Agency's Committee for Medicinal Products for Human Use has been researching the results of a Canadian study that prompted pulling Trasylol from much of the world's market. The Committee has advised that pulling the drug was the correct action.
235 Deaths Linked to Trasylol
Category: Trasylol News
There were 235 reports submitted to the Food and Drug Administration for people that died following the use of the anti-bleeding drug Trasylol. The reports were only for the time period from 1993 to February 2006. The FDA is still reviewing data from March 2006 to the present. Trasylol was pulled from the market last month following a Canadian study that linked it to a higher rate of death.
Bayer to Stop Marketing of Trasylol
Category: Trasylol News
The FDA has asked that Bayer stop all marketing of the drug Trasylol. Trasylol was pulled from the market following a study in Canada that showed an increased risk of death while taking the drug. Trasylol is used to stop bleeding during heart surgery.
Bayer Halts Trasylol Sales After Canadian Study Shows Higher Risk of Death
Category: Trasylol News
Bayer AG, based in Leverkusen, Germany, halted sales and marketing of its drug Trasylol today following a Canadian clinical study showing a potential for higher risk of death in patients who received Trasylol during heart surgery. The drug is administered to patients receiving heart bypass surgery and is designed to minimize blood loss, decreasing the need for blood transfusions.
Bayer made the decision to suspend sales after talks with the U.S. Food and Drug Administration, the German Federal Institute for Drugs and Medicine Products along with Health Canada, and it comes just a month after the FDA recommended that the drug remain on the market.
The FDA approved Trasylol to be used for stopping blood loss in 1993, but it has been linked to other serious side effects, including kidney problems, heart attacks and strokes.
Trasylol - the drug you never knew you took
Category: Trasylol News
It is obvious from the results of our advertising that many people who had heart surgery do not know if they were given Trasylol. Weinform them that if the kidney damge or stroke occurred during or ust after surgery, we should find out. This means getting medical record on the patient, but it is worth the effort. Kidney dialysis is a severe unexpected outcome of heart surgey.
Cases of Trasylol Injury Coming In
Category: Trasylol News
My law firm and a few others are continuing to advertise for Trasylol injury cases. More than few people are responding. One factor affecting people's interest is the fact that they usually don't know that they ever received Trasylol. This being a medication that is delivered during by-pass surgery to control bleeding, the patient is never told specifically what drug is used to control bleeding during the procedure. As more kidney dialysis patients learn that this medication could have played a role in their kidney damage, I imagine we will see even more cases.
Trasylol Victims Finding Lawyers
Category: Trasylol News
Early rounds of attorney advertising for Trasylol cases after the FDA announcments in early February are starting to result in calls to my office. Some people were found to have kidney damage long after their heart sugery and there is probably no causation with the drug Trasylol. However, a few callers learned of kidney damage within a day or two of being released from the hospital. We have seen one case with a kidney related death within 2 weeks of release. These quick onset cases are the ones we will have to investigate further.
The most recent web news ...
FDA is Advising Doctors on Trasylol
Category: Trasylol News
After recent studies, the FDa is finally warning doctors about this blood loss control product.
While the FDA is conducting a further evaluation of this drug in light of the recent publications, it is advising doctors
as follows:
* Physicians who use Trasylol should carefully monitor patients for the occurrence of toxicity, particularly to the kidneys, heart or central nervous system and promptly report adverse event information to Bayer, the drug manufacturer, or through the FDA Medwatch program. * Physicians should consider limiting Trasylol use to those situations in which the clinical benefit of reduced blood loss is essential to medical management of the patient and outweighs the potential risks. * FDA is working with the manufacturer to examine the safety and benefits of Trasylol in light of the recent data and the evolving practice of medicine. * Patients should discuss all major risks for heart bypass surgery with their healthcare providers. These include the risks for bleeding and the available ways to lessen the risk for bleeding.
Bovine Lungs - a Good Trasylol(R) Ingredient?
Category: Trasylol News
Unlike its generic competitors, Trasylol(R) is made from bovine lungs. As studies have now shown, Trasylol is significantly more dangerous than similar drugs used to reduce blood loss. The two generic drugs examined in the New England Journal of Medicine study, aminocaproic acid and tranexamic acid, were found to be significantly safer and just as effective as Trasylol. Did they use Bovine Lungs? Click here to see images of bovine lungs.
Bayer Stock dives on Trasylol news, but why?
Category: Trasylol News
On February , 2006 the FDA's warning on Bayer's Trasylol blood drug caused a small sell off. Within a few minutes, around 700,000 shares were traded. See article.
This is a little surprising, since a study was announced on this back in January with the findings showing the increased risk of this product compared to the generic equivalents. Maybe Bayer was able to "soften" that news until the FDA took action. I wonder when the insiders traded?
FDA Trasylol Health Advisory
Category: Trasylol News
On February 8th the FDA issued a Public Health Advisory for Trasylol (Aprotinin Injection). The Advisory was based on a study found in the New England Journal of Medicine which linked Trasylol to adverse events such as kidney (renal) failure, myocardial infarction, stroke, heart failure and heart attack.